Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia
Completed
- Conditions
- Hypercholesterolemia
- Registration Number
- NCT00687492
- Lead Sponsor
- AstraZeneca
- Brief Summary
The survey will try to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the third NCEP ATP guidelines, overall and by country.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 8000
Inclusion Criteria
- 2 or more risk factors (according to NCEP ATP III guideline)
- Receiving lipid-lowering drug treatment for at least 3 months without dosage change for a minimum of 6 weeks.
Read More
Exclusion Criteria
- Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site).
- Previous enrolment or randomisation of treatment in the present study.
- Participation in a clinical study during the last 90 days.
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The number and percentage of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP Ⅲ guidelines(overall and by country) After collecting all Patient Record Form.
- Secondary Outcome Measures
Name Time Method The number and percentage of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP Ⅲ guidelines for several subject subsets. After collecting all Patient Record Form. The association between achievement of LDL-C goals,according to the updated 2004 NCEP ATPⅢ guidelines and patient and physician variables. After collecting all Patient Record Form. The physician characteristics associated with the allocation of hypercholesterolemia treatment regime. After collecting all Patient Record Form.
Trial Locations
- Locations (1)
Research Site
🇻🇳Hcmc, Vietnam